Biogen Inc.

NASDAQ Global Select
Back to all articles
Somewhat Bullish +50

Biogen stock after-hours at EUR 200.20: minus 0.22 percent versus prior close

Clinical trial results Drug approval Earnings report AI-generated analysis

📉 Biogen stock traded at EUR 200.20 after-hours on September 29, 2026, down 0.22 percent versus the prior close.

📅 The company plans to report third-quarter 2026 financial results before the market opens on October 28, 2026.

✅ Japan approved LEQEMBI Pen, a subcutaneous formulation of lecanemab, for weekly administration in early Alzheimer's disease.

🔬 Biogen and Eisai announced that LEQEMBI Pen uses two 250-milligram pens administered once weekly by patients or care partners.

✅ A prespecified adolescent subgroup analysis from the Phase 3 VALIANT study was published in the Clinical Journal of the American Society of Nephrology.

📊 Among 55 adolescents aged 12 to 17, EMPAVELI produced a 75 percent relative reduction in proteinuria versus placebo at Week 26.

✅ Additionally, 71 percent of adolescent patients achieved at least a 50 percent reduction in proteinuria compared with 4 percent receiving placebo.

🗓️ A management webcast for the upcoming earnings report is scheduled for 8:30 a.m. Eastern Time on October 28, 2026.

Bullish Signals
  • Japan approved LEQEMBI Pen, a subcutaneous formulation of lecanemab, as a new route of administration for early Alzheimer's disease.
  • Biogen and Eisai announced that the LEQEMBI Pen formulation uses two 250-milligram pens administered once weekly, enabling administration by care partners or patients.
  • A prespecified adolescent subgroup analysis from the Phase 3 VALIANT study showed EMPAVELI produced a 75 percent relative reduction in proteinuria versus placebo at Week 26 among adolescents aged 12 to 17.
  • In the same adolescent study, 71 percent of patients achieved at least a 50 percent reduction in proteinuria compared with only 4 percent receiving placebo.
Full Analysis
Biogen Inc. (BIIB) traded at EUR 200.20 in after-hours trading on September 29, 2026, representing a minor decline of 0.22 percent against the prior close. The company is preparing to report its third-quarter 2026 financial results before the market opens on October 28, 2026, with a management webcast scheduled for 8:30 a.m. Eastern Time. Recent regulatory and clinical developments highlight Biogen's progress in key therapeutic areas. In September 2026, Biogen and its partner Eisai announced that Japan approved LEQEMBI Pen, a subcutaneous formulation of lecanemab designed for weekly administration by patients or care partners for early Alzheimer's disease. Additionally, the company reported positive data from a prespecified adolescent subgroup analysis of the Phase 3 VALIANT study regarding its drug EMPAVELI. Published in the Clinical Journal of the American Society of Nephrology, the study showed that among adolescents aged 12 to 17, EMPAVELI achieved a 75 percent relative reduction in proteinuria versus placebo at Week 26. Biogen continues to advance its pipeline with these approvals and data releases, positioning itself for potential growth in neurology and nephrology markets ahead of its upcoming earnings report.